SCHEDULE: Lincoln Alternative Strategies Discloses 7.54% Stake in BioCardia

Lincoln Alternative Strategies LLC has reported a beneficial ownership of 7.54% in BioCardia, Inc., holding 800,000 shares of common stock.

Summary

• Lincoln Alternative Strategies LLC has filed a Schedule 13G, indicating beneficial ownership in BioCardia, Inc.
• The reporting person, Lincoln Alternative Strategies LLC, is based in Delaware.
• The filing reports beneficial ownership of 800,000 shares of BioCardia, Inc. common stock.
• This ownership represents 7.54% of BioCardia's outstanding common stock.
• The beneficial ownership percentage is calculated based on 10,608,734 shares of common stock issued and outstanding as of September 19, 2025.
• Lincoln Alternative Strategies LLC holds sole voting power and sole dispositive power over all 800,000 shares.
• The securities were not acquired for the purpose of changing or influencing control of BioCardia, Inc., nor in connection with any transaction having that purpose, other than activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a significant institutional investor has disclosed a substantial stake, which can be interpreted as a vote of confidence in the company. However, the filing itself does not provide operational or financial performance details.

Positives

• A significant institutional investor, Lincoln Alternative Strategies LLC, has taken a substantial stake in BioCardia, Inc., potentially signaling confidence in the company's future prospects.
• The acquisition of 7.54% of outstanding shares by an alternative strategies firm could attract further investor attention and potentially improve liquidity.

Negatives

• No specific negative financial or operational details are disclosed in this beneficial ownership report.

Risks

• The filing itself does not detail specific risks related to BioCardia, Inc.'s operations or financial health. It is a disclosure of ownership.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from BioCardia, Inc. or Lincoln Alternative Strategies LLC regarding future performance or outlook.

Industry Context

The disclosure of a significant stake by an alternative strategies firm in a biotechnology company like BioCardia, Inc. can be viewed as a vote of confidence in the sector or the specific company's potential, especially in areas like regenerative medicine or cardiovascular therapies where BioCardia operates. Such investments are common as institutional investors seek opportunities in high-growth or specialized industries.

Stakeholder Impact

• **Shareholders:** Existing shareholders may view this as a positive signal, potentially leading to increased investor confidence and interest in BioCardia's stock.
• **Potential Investors:** The disclosure of a significant institutional stake could attract new investors looking for validation from established funds.
• **Company Management:** Management may see this as external validation of their strategy and potential, though it also means increased scrutiny from a large shareholder.

Key Dates

Recommendation

The filing indicates a significant institutional investment, which is generally a positive signal. However, without additional financial or operational performance data from BioCardia, Inc., a 'hold' recommendation is appropriate. The investment suggests potential, but a 'buy' would require more comprehensive analysis of the company's fundamentals and future prospects, which are not detailed in this ownership disclosure. A 'sell' is not warranted as the news is not negative.

Keywords

BioCardia, Lincoln Alternative Strategies, Beneficial Ownership, SEC Filing, Common Stock, Investment, Healthcare, Biotechnology